These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29162675)

  • 41. Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme.
    Yang CF; Liao TE; Chu YL; Chen LZ; Huang LY; Yang TF; Ho HC; Kao SM; Niu DM
    J Med Genet; 2023 May; 60(5):430-439. PubMed ID: 36137614
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The humanistic burden of Pompe disease: are there still unmet needs? A systematic review.
    Schoser B; Bilder DA; Dimmock D; Gupta D; James ES; Prasad S
    BMC Neurol; 2017 Nov; 17(1):202. PubMed ID: 29166883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Outcome of Later-Onset Pompe Disease Identified Through Newborn Screening.
    Lee NC; Chang KL; In 't Groen SLM; de Faria DOS; Huang HJ; Pijnappel WWMP; Hwu WL; Chien YH
    J Pediatr; 2022 May; 244():139-147.e2. PubMed ID: 34995642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
    Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
    Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
    Banugaria SG; Prater SN; Patel TT; Dearmey SM; Milleson C; Sheets KB; Bali DS; Rehder CW; Raiman JA; Wang RA; Labarthe F; Charrow J; Harmatz P; Chakraborty P; Rosenberg AS; Kishnani PS
    PLoS One; 2013; 8(6):e67052. PubMed ID: 23825616
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy.
    Chen CA; Chien YH; Hwu WL; Lee NC; Wang JK; Chen LR; Lu CW; Lin MT; Chiu SN; Chiu HH; Wu MH
    J Card Fail; 2011 Nov; 17(11):930-6. PubMed ID: 22041330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Consensus treatment recommendations for late-onset Pompe disease.
    Cupler EJ; Berger KI; Leshner RT; Wolfe GI; Han JJ; Barohn RJ; Kissel JT;
    Muscle Nerve; 2012 Mar; 45(3):319-33. PubMed ID: 22173792
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
    Stepien KM; Hendriksz CJ; Roberts M; Sharma R
    Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up.
    Spiridigliozzi GA; Heller JH; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):22-9. PubMed ID: 22253038
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Opinions of adults affected with later-onset lysosomal storage diseases regarding newborn screening: A qualitative study.
    Lisi EC; Ali N
    J Genet Couns; 2021 Dec; 30(6):1544-1558. PubMed ID: 33938615
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Three cases of multi-generational Pompe disease: Are current practices missing diagnostic and treatment opportunities?
    McIntosh P; Austin S; Sullivan J; Bailey L; Bailey C; Viskochil D; Kishnani PS
    Am J Med Genet A; 2017 Oct; 173(10):2628-2634. PubMed ID: 28763149
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A new assay for fast, reliable CRIM status determination in infantile-onset Pompe disease.
    Wang Z; Okamoto P; Keutzer J
    Mol Genet Metab; 2014 Feb; 111(2):92-100. PubMed ID: 24044919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Should we consider newborn screening for Pompe disease?].
    Lacombe D; Verloes A
    Arch Pediatr; 2014 Jun; 21(6):561-3. PubMed ID: 24768068
    [No Abstract]   [Full Text] [Related]  

  • 54. The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.
    Lacaná E; Yao LP; Pariser AR; Rosenberg AS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):30-9. PubMed ID: 22253234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
    Schoser B; Stewart A; Kanters S; Hamed A; Jansen J; Chan K; Karamouzian M; Toscano A
    J Neurol; 2017 Apr; 264(4):621-630. PubMed ID: 27372449
    [TBL] [Abstract][Full Text] [Related]  

  • 56. European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience.
    van der Ploeg AT; Kruijshaar ME; Toscano A; Laforêt P; Angelini C; Lachmann RH; Pascual Pascual SI; Roberts M; Rösler K; Stulnig T; van Doorn PA; Van den Bergh PYK; Vissing J; Schoser B;
    Eur J Neurol; 2017 Jun; 24(6):768-e31. PubMed ID: 28477382
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Newborn screening for Pompe disease: impact on families.
    Pruniski B; Lisi E; Ali N
    J Inherit Metab Dis; 2018 Nov; 41(6):1189-1203. PubMed ID: 29594646
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Newborn screening for Pompe disease: synthesis of the evidence and development of screening recommendations.
    Kemper AR; Hwu WL; Lloyd-Puryear M; Kishnani PS
    Pediatrics; 2007 Nov; 120(5):e1327-34. PubMed ID: 17974725
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.